
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

